Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FR‑alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after 1 to 3 lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement (see section 2).
Mirvetuximab soravtansine must be funded in the NHS in England for the condition and population in the recommendation, if it is considered the most suitable treatment option. Mirvetuximab soravtansine must be funded in England within 90 days of final publication of this guidance.
There is enough evidence to show that mirvetuximab soravtansine provides benefits and value for money, so it can be used routinely across the NHS in this population.
NICE has produced tools and resources to support the implementation of this guidance.
Usual treatment for FR‑alpha-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 lines of systemic treatment is chemotherapy.
Clinical trial evidence shows that mirvetuximab soravtansine increases how long people have before their condition gets worse and how long they live compared with chemotherapy.
When considering the condition's severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, mirvetuximab soravtansine can be used.